Vitafoods Europe 2026: clinical proof, the new ticket to entry for food brands.

Vitafoods Europe is something like the fashion week of ingredients. A B2B show where what B2C food brands will put on shelf in 2027 gets chosen. And this year, the watchword is clinical proof.

Consumers no longer buy a promise. They buy proof that is sourced, traceable and measurable. Three ingredients seen in Barcelona show how that proof is being industrialized. And one question hangs in the air: these cutting-edge ingredients are, to varying degrees, ultra-processed in the sense of the NOVA classification. The 2027 challenge will no longer be only to prove efficacy, but to keep that promise while owning the process.

Clean label is no longer enough.

Clean label on its own has become a minimum entry point. No longer a differentiator. The new consumer requirement is proof that is sourced, traceable and measurable. Vitafoods 2026 confirmed this shift through its Startup Challenge winners, whose arguments all rest on clinical data: bioavailability, mechanism of action, randomized studies.

The BIAM 2026 barometer, run by Nutrikéo and ProtéinesXTC, formalizes it through the theme Me, Myself & I: consumers want personalized data, not a generic promise. Two statistics to grasp the stakes:

• 1 consumer in 3 is moving into a health self-care mindset (Innova Market Insights, Global Ingredient Trends 2026).
• 30% of Gen Z trust third-party apps like Yuka more than brand labels (NielsenIQ via Imagen Insights, May 2026).

On the market side, food supplements in France were worth €2.7B in 2023, growing 3% a year, with the pharmacy channel climbing faster than e-commerce. The B2B nutraceutical bridge to B2C food is no longer a hypothesis: it is an infrastructure being deployed.

The four Startup Challenge winners.

Four categories. Four winners selected by an international jury (Pedro Alvarez Bretones, Nard Clabbers, Michael Stott, Mariette Abrahams, Mike Dovbish, and the French voice Grégory Dubourg of Nutrikéo and ProtéinesXTC). The common thread: every winner argues from science, never from marketing.

The three pathways to proof going mainstream.

Beyond the official winners, three ingredients seen in Barcelona illustrate the three main pathways by which clinical proof now scales to industrial level.

Three pathways, one verdict: clinical proof is no longer a niche argument. It is becoming market infrastructure. Food brands that fail to prepare their proof plan as early as 2026 will fall behind in a way that is hard to recover by 2028.

The NOVA caveat, a 2027 challenge.

These three ingredients deliver what they promise. But they are, to varying degrees, ultra-processed in the sense of the NOVA classification (Monteiro et al., the framework used by EFSA and the WHO). The European Food Safety Authority and the WHO already rely on this classification for their reference frameworks.

For food brands, the 2027 challenge will not only be to prove efficacy. It will be to keep that promise while owning the process. Even when the label reads NOVA 4. The tension point left unresolved at Vitafoods 2026.

A new editorial stance has yet to be invented. Three avenues to explore now for French food brands:

• Own the process by telling the science in plain words, against the fear of the "ultra-processed" label.
• Reframe the claims so they convey both the proven efficacy and the nature of the process.
• Invest in clinical data to back the label against the pressure of third-party apps (Yuka, Open Food Facts).

5 jobs to be done to activate.

At the crossroads of the Vitafoods signals, the Innova Top Trends 2026 and the BIAM barometer, five jobs to be done emerge. Each opens a brand territory for a French food SME or mid-cap.

Threats to anticipate, opportunities to seize.

The strategic question.

Of these three proof pathways, which one is entering your product brief? And how are you preparing to justify it against the NOVA reading?

Clinical proof is no longer a luxury. It has become the standard. The brand that cannot demonstrate it in 2027 will pay for that lag for five years. The conclusion you draw after three days in Barcelona.

For French food SMEs and mid-caps, three priorities to write into the 2026-2027 plan:

1. Map your category onto the three proof pathways. Which one fits your existing product asset? Which one opens an adjacent category?
2. Build a clinical-proof plan. Studies available in the literature, academic partnerships, internal consumer micro-studies.
3. Prepare the NOVA narrative. Anticipate the reading by third-party apps and openly communicate the process.

On these three priorities, the head-start window is closing fast. The first to act will gain 18 months on the rest.